# A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

> **NCT00541658** · PHASE3 · COMPLETED · sponsor: **Warner Chilcott** · enrollment: 923 (actual)

## Conditions studied

- Postmenopausal Osteoporosis

## Interventions

- **DRUG:** risedronate
- **DRUG:** risedronate
- **DRUG:** risedronate

## Key facts

- **NCT ID:** NCT00541658
- **Lead sponsor:** Warner Chilcott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 923 (ACTUAL)
- **Last updated:** 2013-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00541658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00541658, "A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00541658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*